TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03982121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 5 or 10 or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 5 or 10 or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 5 or 10 or 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: GLA-SE 1 or 2 or 5 or 10 or 20 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: GLA-SE 1 or 2 or 5 or 10 or 20 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: GLA-SE 1 or 2 or 5 or 10 or 20 μg
Study: NCT00551642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide
Description: Nitric Oxide vapour (gas) for inhalation (400 ppm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gas for inhalation
Study: NCT04225195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B cholesteryl sulfate complex for injection(ABCD)
Description: IC patients will only receive intravenous treatment with ABCD, with the longest course of treatment up to 42 days. ABCD will be administered once a day at a dose of 3-4 mg/kg. Visit plan: screening period (D-4 to D-1), baseline period (D1), treatment period and follow-up period (14±3days after the end of the last dose of ABCD).~IA patients will be treated with ABCD for 4 weeks first, followed by oral administration of voriconazole. The total course of treatment should be at least 6 to 12 weeks. ABCD dosing regimen will be the same as that for IC patients. Visiting plan: screening period (D-4to D-1), baseline period (D1), treatment period and follow-up period.
Study: NCT04351334

Intervention type: DRUG
Intervention: Alectinib
Description: Observational treatment based on physician choice
Study: NCT01808586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: 6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4mg/mL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Lidocaine
Description: 2%

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Standardized home exercise program
Study: NCT04013997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EksoGT
Description: The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
Study: NCT01547923

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sample for phenotypic and pharmacogenetic analysis.
Description: Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).

Intervention type: GENETIC
Group type: OTHER
Intervention: Blood sample for phenotypic and pharmacogenetic analysis.
Description: Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
Study: NCT04828681

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.
Study: NCT02512705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinel Restraints

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Seclusion Room
Study: NCT01751529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Ultrasound
Description: All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid
Description: All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
Study: NCT03193255

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPHTECS cleadew GP
Description: Povidone-iodine based disinfecting solutions for rigid contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPHTECS cleadew GP
Description: Povidone-iodine based disinfecting solutions for rigid contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPHTECS cleadew GP
Description: Povidone-iodine based disinfecting solutions for rigid contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPHTECS cleadew GP
Description: Povidone-iodine based disinfecting solutions for rigid contact lenses
Study: NCT04771806

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT01598311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-183,315
Description: CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo size 00 opaque hard gelatin capsules.
Study: NCT02368678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planning (SRP)
Description: Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Mouth Scaling (FMS)
Description: Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants.
Study: NCT00978627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
Study: NCT02188420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Magstim)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (Magstim)
Study: NCT02560311

Intervention type: OTHER
Intervention: observation
Study: NCT00095498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: For subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: For subcutaneous injection
Study: NCT00346671

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: 30 min supine rest

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 30 min session with Sham practitioner

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: 30 min session with Reiki practitioner
Study: NCT03258684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone, Vitamin C, and Thiamine
Description: Intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT02301715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
Study: NCT02666469

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy (HBOT) and Exercise Program
Description: HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Multiplace Chamber
Description: Patients will receive treatment in a multiplace Hyperbaric Chamber
Study: NCT02708654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic pill bottle
Description: Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bluetooth scale
Description: Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Partner
Description: Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement incentives
Description: Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
Study: NCT03620331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery with a previous non-surgical approach
Description: Non-surgical phase done prior to the surgical treatment of peri-implantitis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery without a previous non-surgical approach
Description: Non-surgical phase not done prior to the surgical treatment of peri-implantitis
Study: NCT02946190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertagen® aP + Td-pur®
Description: see arm/group descriptions

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix® dTpa
Description: see arm/group descriptions
Study: NCT04351737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracanalicular Dexamethasone, (0.4 mg) Insert
Description: To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate
Description: To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
Study: NCT00452426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)
Description: propofol sedation per device instructions for use

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: benzodiazepines and opioid sedation
Description: per site's current standard of care
Study: NCT03541174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 12.5 mg
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: Tablet, oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: Tablet, oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT00153062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aggrenox
Description: 25mg aspirin, 200 mg dipyridamole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aggrenox
Description: 25mg aspirin, 200 mg dipyridamole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micardis
Description: 80 mg micardis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micardis
Description: 80 mg micardis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aggrenox placebo
Description: placebo
Study: NCT04771806

Intervention type: OTHER
Intervention: Neurocognitive Assessment
Description: Undergo neurocognitive testing

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00732056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN163L
Description: 25% dose escalation infused over 2 hours weekly
Study: NCT03460795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC and Tregs
Description: conventional plus MSC and Tregs or placebo treatment
Study: NCT04466943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular transmission monitoring (NMT)
Description: NMT is to monitor the depth of neuromuscular blockade intensity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular transmission monitoring (NMT)
Description: NMT is to monitor the depth of neuromuscular blockade intensity
Study: NCT01751698

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASP-EMT
Description: JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTT
Description: CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
Study: NCT01409707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused exposure therapy
Description: cognitive behavioral therapy for PTSD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational enhancement + trauma-focused exposure therapy
Description: Cognitive behavioral therapy for PTSD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyles sessions
Study: NCT02220920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (TA-7284)
Description: The patients will receive Canagliflozin orally for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive Placebo orally for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Study: NCT01213563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actrapid insulin+Gloucose
Description: On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actrapid insulin
Description: On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
Study: NCT00648440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine HCl Tablets 5 mg
Description: 5mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAmatine® Tablets 5 mg
Description: 5mg, single dose fed
Study: NCT01646580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclopirox
Description: Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
Study: NCT04611386

Intervention type: DRUG
Intervention: computerized tomography
Description: Anti Factor Xa level

Intervention type: DRUG
Intervention: computerized tomography
Description: Anti Factor Xa level

Intervention type: DRUG
Intervention: computerized tomography
Description: Anti Factor Xa level

Intervention type: DRUG
Intervention: computerized tomography
Description: Anti Factor Xa level